Tumor-specific surface antigen

Tumor-specific surface antigens are proteins or peptides that are found exclusively on the surface of cancer cells and not on normal cells[1][2][4][7]. They commonly arise from somatic mutations unique to tumor cells, such as point mutations, fusion genes, or are derived from oncogenic viral proteins, resulting in so-called "neoantigens"[1][2][6]. Because they are absent from healthy tissues, they represent highly attractive and specific targets for cancer immunotherapies, including cancer vaccines, adoptive T-cell therapies, and some monoclonal antibodies[1][4][7]. TSAs are fundamentally a molecular class of antigen, not a single molecule or defined protein, but instead a broad category comprising a diverse array of potential targetable structures whose identities are tumor- and patient-specific[5][6][7]. While their specificity offers reduced risk of autoimmune toxicity, practical challenges include their heterogeneity, variability between patients and tumors, difficulty detecting and validating immunogenic TSAs, and the risk that tumor cells can lose or down-regulate expression to escape immune attack[6][7]. “Tumor-specific surface antigen” is not a single molecular entity but a category; as such, use in structured datasets is not appropriate as a canonical molecular target and must be mapped to specific protein/protein variant wherever possible. Additional notes: - The term “tumor-specific surface antigens” is not a unique molecular target, but a broad functional classification; therefore, it does not map to a single gene or protein, and the entry is considered “incorrect” or nonspecific for structured target curation purposes[2][6][7]. - Common examples of specific TSAs implicated in immunotherapy development include neoantigen variants of oncogenes (KRAS, EGFR mutants), fusion proteins (BCR-ABL from chromosomal translocations), or viral antigens (HPV E6/E7 in cervical carcinoma)[1][2][4]. These should be named specifically in structured datasets. If you need structured data for a specific TSA (e.g., mutant KRAS G12D), please specify the exact antigen.

Other names

Tumor-specific antigenTSANeoantigen (for mutated forms)Cancer neoantigen

Immune-mediated cell killing by cytotoxic T lymphocytes recognizing tumor-specific antigens Activation of tumor-targeting immune responses via vaccination with TSA peptides or proteins CAR-T or TCR therapy targeting TSAs